{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:29:50Z","timestamp":1695540590794},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1097\/mca.0000000000000623","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T16:49:59Z","timestamp":1523551799000},"page":"469-476","source":"Crossref","is-referenced-by-count":4,"title":["Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes"],"prefix":"10.1097","volume":"29","author":[{"given":"Andrew T.","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Neely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek D.","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorairaj","family":"Prabhakaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik M.","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210204","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-4-20210204","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-4-20210204","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-4-20210204","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"R5-4-20210204","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2015","journal-title":"Eur Heart J"},{"key":"R6-4-20210204","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.cjca.2013.07.001","article-title":"Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy","volume":"29","author":"Tanguay","year":"2013","journal-title":"Can J Cardiol"},{"key":"R7-4-20210204","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"R8-4-20210204","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ahj.2010.04.022","article-title":"Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina\/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial","volume":"160","author":"Chin","year":"2010","journal-title":"Am Heart J"},{"key":"R9-4-20210204","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ahj.2007.07.040","article-title":"Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome","volume":"154","author":"Yan","year":"2007","journal-title":"Am Heart J"},{"key":"R10-4-20210204","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jama.299.5.532","article-title":"Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome","volume":"299","author":"Ho","year":"2008","journal-title":"JAMA"},{"key":"R11-4-20210204","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCOUTCOMES.109.919415","article-title":"Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge","volume":"3","author":"Bagnall","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R12-4-20210204","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCOUTCOMES.114.001223","article-title":"Early medication nonadherence after acute myocardial infarction: insights into actionable opportunities from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study","volume":"8","author":"Mathews","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R13-4-20210204","first-page":"303","article-title":"Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study","volume":"3","author":"Russo","year":"2017","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R14-4-20210204","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jacc.2013.12.012","article-title":"Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention","volume":"63","author":"Wang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R15-4-20210204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe1112770","article-title":"A new era in secondary prevention after acute coronary syndrome","volume":"366","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"R16-4-20210204","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jcin.2014.10.017","article-title":"Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy","volume":"8","author":"Cutlip","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"R17-4-20210204","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0735-1097(00)00808-1","article-title":"Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events","volume":"36","author":"Goodman","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R18-4-20210204","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/euhj.2001.2779","article-title":"Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE","volume":"23","author":"Antman","year":"2002","journal-title":"Eur Heart J"},{"key":"R19-4-20210204","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ahj.2005.05.003","article-title":"Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial","volume":"151","author":"Fitchett","year":"2006","journal-title":"Am Heart J"},{"key":"R20-4-20210204","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"R21-4-20210204","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"R22-4-20210204","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:42:49Z","timestamp":1620960169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201809000-00004"}},"subtitle":["insights from the TRILOGY ACS trial"],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000623","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}